Idursulfase
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Idursulfase (brand name Elaprase) is a drug used to treat Hunter syndrome (also called Mucopolysaccharoidosis II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced. Initial yearly costs were reported to be $300,000.[2]
It is manufactured by Shire Pharmaceuticals Group.
References
- ↑ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
- ↑ "Drug approved to treat rare but potentially deadly disease". Retrieved 2007-09-02.
External links
- idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)
Template:Other alimentary tract and metabolism products sv:Elaprase
Categories:
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Orphan drugs